Please provide your email address to receive an email when new articles are posted on . Patients that were white, Black, Asian or “other” achieved similar efficacy results with Skyrizi. Similar ...
AbbVie (NYSE:ABBV) announced Wednesday that its FDA-approved immunology therapy, Skyrizi, outperformed Amgen’s (NASDAQ:AMGN) blockbuster therapy, Otezla, in a Phase 4 head-to-head study for adults ...
Everyday Health on MSN
Don’t Give Up on Finding the Right Psoriasis Treatment
Discover tips on navigating psoriasis treatments with resilience. Learn from a personal journey through six biologics, emphasizing hope and perseverance.
In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...
Credit: Thinkstock. Risankizumab is an interlekin-23 inhibitor; apremilast is a phosphodiesterase 4 inhibitor. Risankizumab (Skyrizi ®) was found to significantly improve clinical outcomes in patients ...
AbbVie Inc ABBV announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi (risankizumab) ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback